Short- and long-term efficacy and safety of risperidone in adults with disruptive behavior disorders
✍ Scribed by Carllo Gagiano; Stephen Read; Lilian Thorpe; Mariëlle Eerdekens; Ilse Van Hove
- Publisher
- Springer
- Year
- 2005
- Tongue
- English
- Weight
- 126 KB
- Volume
- 179
- Category
- Article
- ISSN
- 0033-3158
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract This subgroup analysis of the 6‐month, open‐label Switch to Risperidone Microspheres (StoRMi) trial evaluated long‐term safety and efficacy of a direct conversion to risperidone long‐acting injectable (RLAI) in 52 elderly patients (≥65 years) with psychosis stabilized on oral or depot a
## Abstract ## Background Elderly patients are often an underserved population in terms of optimizing treatment outcomes. Long‐acting risperidone, the first long‐acting injectable atypical antipsychotic, can improve outcomes through continuous medication delivery. ## Objective To assess the effi